Table 1.
Characteristics of the HBV-HIV co-infected versus HBV mono-infected North American adult samples, stratified by HBeAg status.
| HBeAg(+) | HBeAg(−) | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| HBV-HIV N=58 |
HBV-only N=58 |
P | HBV-HIV N=47 |
HBV-only N=47 |
P | |
| Age (years) | 0.84 | 0.74 | ||||
| Median (25th, 75th) | 50 (45, 56) | 49 (43, 58) | 49 (44, 56) | 47 (43, 57) | ||
| Sex, n (%) | <.001 | |||||
| Male | 51 (87.9) | 31 (53.4) | 47 (100.0) | 47 (100.0) | ||
| Female | 7 (12.1) | 27 (46.6) | 0 (0.0) | 0 (0.0) | ||
| Race, n (%) | n=57 | <.001 | n=46 | <.001 | ||
| Non-Hispanic White | 24 (42.1) | 8 (13.8) | 16 (34.8) | 5 (10.6) | ||
| Non-Hispanic Black | 26 (45.6) | 3 (5.2) | 26 (56.5) | 5 (10.6) | ||
| Non-Hispanic Asian | 2 (3.5) | 45 (77.6) | 3 (6.5) | 36 (76.6) | ||
| Other | 5 (8.8) | 2 (3.4) | 1 (2.2) | 1 (2.1) | ||
| Estimated transmission mode | n=53 | n=45 | <.001 | n=38 | n=28 | <.001 |
| Vertical | 0 (0.0) | 30 (66.7) | 1 (2.6) | 15 (53.6) | ||
| Horizontal | 53 (100.0) | 14 (31.1) | 37 (97.4) | 13 (46.4) | ||
| Other | 0 (0.0) | 1 (2.2) | 0 (0.0) | 0 (0.0) | ||
| Estimated years of HBV | n=43 | n=42 | <.001 | n=36 | n=26 | <.001 |
| Median (25th, 75th) | 15 (8, 20) | 39 (29, 53) | 13 (8, 22.5) | 37 (21, 47) | ||
| HBV therapy, n (%) | 0.049 | 0.008 | ||||
| Tenofovir alone/combination | 52 (89.7) | 44 (75.9) | 41 (87.2) | 29 (61.7) | ||
| Entecavir alone/or with Lamivudine | 6 (10.3) | 14 (24.1) | 3 (6.4) | 16 (34.0) | ||
| Emtricitabine alone | 0 (0.0) | 0 (0.0) | 1 (2.1) | 0 (0.0) | ||
| Lamivudine alone | 0 (0.0) | 0 (0.0) | 2 (4.3) | 2 (4.3) | ||
| ALT x ULN | n=57 | 0.68 | n=44 | n=46 | 0.18 | |
| ≤1 | 32 (56.1) | 23 (39.7) | 26 (59.1) | 19 (41.3) | ||
| >1-2 | 16 (28.1) | 32 (55.2) | 15 (34.1) | 24 (52.2) | ||
| >2-5 | 8 (14.0) | 2 (3.4) | 3 (6.8) | 3 (6.5) | ||
| >5 | 1 (1.8) | 1 (1.7) | 0 (0.0) | 0 (0.0) | ||
| AST (U/L) | n=57 | n=55 | 0.97 | n=44 | n=46 | 0.80 |
| Median (25th, 75th) | 29 (22, 33) | 28 (23, 33) | 26.5 (21, 42) | 28 (23, 35) | ||
| Total Bilirubin (mg/dL) | n=56 | n=56 | 0.07 | n=44 | n=46 | 0.006 |
| Median (25th, 75th) | 0.5 (0.3, 0.7) | 0.6 (0.4, 0.8) | 0.4 (0.3, 0.7) | 0.7 (0.5, 0.9) | ||
| Albumin (g/dL) | n=57 | n=54 | 0.02 | n=44 | n=45 | 0.03 |
| Median (25th, 75th) | 4.4 (4.1, 4.7) | 4.3 (4.0, 4.5) | 4.3 (4.1, 4.5) | 4.5 (4.3, 4.7) | ||
| Platelets (x103/mm3) | n=57 | n=38 | 0.13 | n=44 | n=32 | 0.34 |
| Median (25th, 75th) | 201 (182, 261) | 198.5 (163, 247) | 203 (175.5, 228.5) | 190.5 (164, 229.5) | ||
| HBV DNA (IU/mL) | 0.24 | 0.01 | ||||
| <20 | 31 (53.4) | 34 (58.6) | 39 (83.0) | 46 (97.9) | ||
| 20 - <1000 | 20 (34.5) | 22 (37.9) | 8 (17.0) | 1 (2.1) | ||
| 1000-<10,000 | 7 (12.1) | 2 (3.4) | 0 (0.0) | 0 (0.0) | ||
Acronyms: ALT, Alanine Aminotransferase; AST, Aspartate aminotransferase; DNA, Deoxyribonucleic acid; HBV, Hepatitis B virus; HCV, HIV, Human immunodeficiency virus;